Overexpression of TAZ Promotes Cell Proliferation, Migration and Epithelial-mesenchymal Transition in Ovarian Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2016 Sep 3

PMID 27588129

Citations 19

Authors

Guangyuan Chen

Jiabin Xie

Ping Huang

Zhihong Yang

Affiliations

Soon will be listed here.

Abstract

The Hippo pathway is dysregulated in multiple types of human cancer, including ovarian cancer. Nuclear expression of yes-associated protein 1 (YAP1), a downstream transcription coactivator of the Hippo pathway, has been demonstrated to promote tumorigenesis in ovarian cancer and may serve as a poor prognostic indicator. However, transcriptional coactivator with PDZ binding motif (TAZ), a downstream target of the Hippo pathway and paralog of YAP in mammalian cells, has not been fully investigated in ovarian cancer. The present study aimed to investigate the dysregulation and biological function of TAZ in ovarian cancer. Reverse transcription-quantitative polymerase chain reaction and western blotting revealed that TAZ mRNA and protein levels, respectively, were upregulated in ovarian cancer, and a meta-analysis of ovarian cancer microarray datasets identified that increased expression of TAZ mRNA is correlated with poor prognosis in patients with ovarian cancer. In addition, TAZ-knockdown in ovarian cancer cells demonstrated that TAZ regulates the migration, proliferation and epithelial-mesenchymal transition of ovarian cancer cells. Furthermore, pharmacological disruption of the YAP/TAZ/TEA domain protein complex resulted in a decrease in ovarian cancer cell migration, proliferation and vimentin expression. The results of the present study indicate that the overexpression of TAZ is important in the development and progression of ovarian cancer, and may function as a potential drug target for treatment of this disease entity.

Citing Articles

Regulation of Tumor Microenvironment through YAP/TAZ under Tumor Hypoxia.

Choi S, Kim D Cancers (Basel). 2024; 16(17).

PMID: 39272887 PMC: 11394240. DOI: 10.3390/cancers16173030.

TAZ is involved in breast cancer cell migration via regulating actin dynamics.

Choi H, Jang H, Kristensen M, Kwon T Front Oncol. 2024; 14:1376831.

PMID: 38774409 PMC: 11106448. DOI: 10.3389/fonc.2024.1376831.

Amplification of Hippo Signaling Pathway Genes Is Governed and Implicated in the Serous Subtype-Specific Ovarian Carcino-Genesis.

Balakrishnan K, Chen Y, Dong J Cancers (Basel). 2024; 16(9).

PMID: 38730733 PMC: 11082992. DOI: 10.3390/cancers16091781.

Tumor-associated fibrosis: a unique mechanism promoting ovarian cancer metastasis and peritoneal dissemination.

Fujimoto H, Yoshihara M, Rodgers R, Iyoshi S, Mogi K, Miyamoto E Cancer Metastasis Rev. 2024; 43(3):1037-1053.

PMID: 38546906 PMC: 11300578. DOI: 10.1007/s10555-024-10169-8.

Role of DCLK1/Hippo pathway in type II alveolar epithelial cells differentiation in acute respiratory distress syndrome.

Chen X, Kao C, Peng S, Chang J, Lee Y, Laiman V Mol Med. 2023; 29(1):159.

PMID: 37996782 PMC: 10668445. DOI: 10.1186/s10020-023-00760-0.

References

Zhang H, Liu C, Zha Z, Zhao B, Yao J, Zhao S . TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem. 2009; 284(20):13355-13362. PMC: 2679435. DOI: 10.1074/jbc.M900843200. View

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

Hall C, Wang R, Miao J, Oliva E, Shen X, Wheeler T . Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 2010; 70(21):8517-25. PMC: 2970655. DOI: 10.1158/0008-5472.CAN-10-1242. View

Hossain Z, Mohamed Ali S, Ko H, Xu J, Peng Ng C, Guo K . Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proc Natl Acad Sci U S A. 2007; 104(5):1631-6. PMC: 1785239. DOI: 10.1073/pnas.0605266104. View

Morin-Kensicki E, Boone B, Howell M, Stonebraker J, Teed J, Alb J . Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol. 2005; 26(1):77-87. PMC: 1317614. DOI: 10.1128/MCB.26.1.77-87.2006. View

Cho K, Shih I . Ovarian cancer. Annu Rev Pathol. 2008; 4:287-313. PMC: 2679364. DOI: 10.1146/annurev.pathol.4.110807.092246. View

Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins R, Chaudhry S . Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013; 15(6):637-46. PMC: 3836234. DOI: 10.1038/ncb2756. View

Gyorffy B, Lanczky A, Szallasi Z . Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012; 19(2):197-208. DOI: 10.1530/ERC-11-0329. View

Kanai F, Marignani P, Sarbassova D, Yagi R, Hall R, Donowitz M . TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J. 2000; 19(24):6778-91. PMC: 305881. DOI: 10.1093/emboj/19.24.6778. View

10.

Harvey K, Zhang X, Thomas D . The Hippo pathway and human cancer. Nat Rev Cancer. 2013; 13(4):246-57. DOI: 10.1038/nrc3458. View

11.

Seo E, Basu-Roy U, Gunaratne P, Coarfa C, Lim D, Basilico C . SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteo-adipo lineage. Cell Rep. 2013; 3(6):2075-87. PMC: 5053763. DOI: 10.1016/j.celrep.2013.05.029. View

12.

Plouffe S, Hong A, Guan K . Disease implications of the Hippo/YAP pathway. Trends Mol Med. 2015; 21(4):212-22. PMC: 4385444. DOI: 10.1016/j.molmed.2015.01.003. View

13.

He C, Lv X, Hua G, Lele S, Remmenga S, Dong J . YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression. Oncogene. 2015; 34(50):6040-54. PMC: 4580488. DOI: 10.1038/onc.2015.52. View

14.

Xia Y, Chang T, Wang Y, Liu Y, Li W, Li M . YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PLoS One. 2014; 9(3):e91770. PMC: 3951505. DOI: 10.1371/journal.pone.0091770. View

15.

Xia Y, Zhang Y, Yu C, Chang T, Fan H . YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells. PLoS One. 2014; 9(11):e109575. PMC: 4219672. DOI: 10.1371/journal.pone.0109575. View

16.

Zhao B, Ye X, Yu J, Li L, Li W, Li S . TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008; 22(14):1962-71. PMC: 2492741. DOI: 10.1101/gad.1664408. View

17.

Brodowska K, Al-Moujahed A, Marmalidou A, Meyer Zu Horste M, Cichy J, Miller J . The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Exp Eye Res. 2014; 124:67-73. PMC: 4135181. DOI: 10.1016/j.exer.2014.04.011. View

18.

Lei Q, Zhang H, Zhao B, Zha Z, Bai F, Pei X . TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol. 2008; 28(7):2426-36. PMC: 2268418. DOI: 10.1128/MCB.01874-07. View

19.

Zhang X, George J, Deb S, Degoutin J, Takano E, Fox S . The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 2011; 30(25):2810-22. DOI: 10.1038/onc.2011.8. View

20.

Cannistra S . Cancer of the ovary. N Engl J Med. 2004; 351(24):2519-29. DOI: 10.1056/NEJMra041842. View